Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Feb 06 • 04:00PM ET

100.47

+2.24 2.28 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.86	Insider Own	12.15%	Shs Outstand	51.31M	Perf Week	-2.66%
Market Cap	5.19B	Forward P/E	-	EPS next Y	-0.06	Insider Trans	-2.93%	Shs Float	45.40M	Perf Month	22.55%
Enterprise Value	5.14B	PEG	-	EPS next Q	0.04	Inst Own	96.72%	Short Float	16.72%	Perf Quarter	43.34%
Income	-41.42M	P/S	11.01	EPS this Y	86.38%	Inst Trans	5.95%	Short Ratio	9.92	Perf Half Y	67.95%
Sales	471.79M	P/B	17.65	EPS next Y	77.38%	ROA	-5.70%	Short Interest	7.59M	Perf YTD	27.19%
Book/sh	5.69	P/C	13.83	EPS next 5Y	-	ROE	-15.81%	52W High	105.74 -4.98%	Perf Year	92.18%
Cash/sh	7.27	P/FCF	117.16	EPS past 3/5Y	12.58% 4.14%	ROIC	-6.80%	52W Low	36.88 172.42%	Perf 3Y	320.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	79.85%	Volatility	4.26% 4.46%	Perf 5Y	429.63%
Dividend TTM	-	EV/Sales	10.89	EPS Y/Y TTM	58.63%	Oper. Margin	-8.86%	ATR (14)	3.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.16	Sales Y/Y TTM	53.66%	Profit Margin	-8.78%	RSI (14)	64.13	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	117.12%	SMA20	4.05%	Beta	0.52	Target Price	114.70
Payout	-	Debt/Eq	1.09	Sales Q/Q	47.17%	SMA50	21.64%	Rel Volume	0.77	Prev Close	98.23
Employees	322	LT Debt/Eq	1.08	Earnings	Nov 04 AMC	SMA200	52.94%	Avg Volume	764.88K	Price	100.47
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	135.66% 1.93%	Trades		Volume	588,660	Change	2.28%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
02:27PM	Loading…
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
11:55AM	Loading…
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
10:15AM	Loading…
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)
07:31AM	Mirum drug for rare genetic disease gains FDA approval (BioPharma Dive)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM

Open in Screener

MBX

MBX Biosciences Inc

Feb 06 • 04:00PM ET

37.67

+1.62 4.49 %

Healthcare • Biotechnology • USA • NASD

MBX MBX Biosciences Inc daily Stock Chart

Held by: VTI IWM IWN VXF IBB XPH VTWO SCHA IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-2.39	Insider Own	41.02%	Shs Outstand	44.72M	Perf Week	2.23%
Market Cap	1.69B	Forward P/E	-	EPS next Y	-2.95	Insider Trans	3.99%	Shs Float	26.48M	Perf Month	15.73%
Enterprise Value	1.30B	PEG	-	EPS next Q	-0.63	Inst Own	70.10%	Short Float	8.72%	Perf Quarter	67.05%
Income	-80.50M	P/S	-	EPS this Y	57.10%	Inst Trans	24.56%	Short Ratio	2.90	Perf Half Y	238.45%
Sales	0.00M	P/B	4.35	EPS next Y	-18.35%	ROA	-23.59%	Short Interest	2.31M	Perf YTD	19.44%
Book/sh	8.67	P/C	4.32	EPS next 5Y	14.35%	ROE	-24.43%	52W High	44.89 -16.08%	Perf Year	234.84%
Cash/sh	8.72	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-20.75%	52W Low	4.81 683.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.68% 8.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.79%	Oper. Margin	-	ATR (14)	2.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.59	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	32.95	EPS Q/Q	-16.28%	SMA20	-1.63%	Beta	0.97	Target Price	61.10
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	11.19%	Rel Volume	0.43	Prev Close	36.05
Employees	43	LT Debt/Eq	0.00	Earnings	Nov 06 BMO	SMA200	95.50%	Avg Volume	795.39K	Price	37.67
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.95% -	Trades		Volume	343,790	Change	4.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$66
Dec-04-25	Initiated	Goldman	Sell	$18
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy	$50
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Show Previous Ratings

Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Loading…
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
08:00AM	Loading…
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:37AM	Loading…
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28 08:03 AM
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21 05:43 PM
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20 04:44 PM
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

Feb 06 • 04:00PM ET

27.32

+1.25 4.79 %

Healthcare • Biotechnology • USA • NASD

ARQT Arcutis Biotherapeutics Inc daily Stock Chart

Peers: BMRN ANAB RCUS BCRX TVRD CNTA DERM VERU SLNO KZIA

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	12.12%	Shs Outstand	120.29M	Perf Week	7.69%
Market Cap	3.35B	Forward P/E	59.19	EPS next Y	0.46	Insider Trans	-3.29%	Shs Float	107.64M	Perf Month	-7.64%
Enterprise Value	3.27B	PEG	-	EPS next Q	0.08	Inst Own	91.73%	Short Float	14.14%	Perf Quarter	12.06%
Income	-44.32M	P/S	10.53	EPS this Y	83.21%	Inst Trans	-1.86%	Short Ratio	7.72	Perf Half Y	93.48%
Sales	317.93M	P/B	20.79	EPS next Y	336.97%	ROA	-10.97%	Short Interest	15.22M	Perf YTD	-5.92%
Book/sh	1.31	P/C	17.49	EPS next 5Y	-	ROE	-28.17%	52W High	31.77 -14.01%	Perf Year	107.28%
Cash/sh	1.56	P/FCF	-	EPS past 3/5Y	34.80% -0.98%	ROIC	-16.36%	52W Low	11.13 145.46%	Perf 3Y	62.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.96%	Volatility	4.24% 4.52%	Perf 5Y	-23.22%
Dividend TTM	-	EV/Sales	10.28	EPS Y/Y TTM	80.35%	Oper. Margin	-12.03%	ATR (14)	1.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.28	Sales Y/Y TTM	129.21%	Profit Margin	-13.94%	RSI (14)	53.94	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.50	EPS Q/Q	116.70%	SMA20	3.91%	Beta	1.67	Target Price	31.75
Payout	-	Debt/Eq	0.72	Sales Q/Q	121.69%	SMA50	-3.27%	Rel Volume	0.65	Prev Close	26.07
Employees	342	LT Debt/Eq	0.71	Earnings	Feb 25 AMC	SMA200	37.27%	Avg Volume	1.97M	Price	27.32
IPO	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	164.10% 14.08%	Trades		Volume	1,286,974	Change	4.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Goldman	Neutral	$18
Dec-30-24	Initiated	H.C. Wainwright	Buy	$19
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Feb-05-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:00AM	Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Jan-27-26 08:16AM	Arcutis Biotherapeutics announces termination of promotion agreement with Kowa (TipRanks)
Jan-26-26 08:00AM	Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa (GlobeNewswire)
Jan-22-26 04:00PM	Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference (GlobeNewswire)
08:00AM	Loading…
Jan-21-26 08:00AM	Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions (GlobeNewswire)
Jan-13-26 04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 08:00AM	Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire) -5.10%
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-14-25 09:35AM	This Biotech Stock Could Cure Your Portfolio's Pain (Motley Fool)
Dec-10-25 12:00PM	What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-08-25 04:00PM	Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri (GlobeNewswire)
10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Loading…
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
Dec-04-25 09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:12AM	Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-28-25 09:33AM	Netflix target cut, Five Below target raised: Wall Street's top analyst calls (The Fly)
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 03:47AM	Why Shares in Arcutis Biotherapeutics Surged Again This Week (Motley Fool) +7.90%
11:38AM	Loading…
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
09:49AM	MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC (Zacks)
09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
Nov-18-25 11:42AM	VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know (Zacks)
10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-17-25 09:41AM	Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
08:00AM	FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Nov-15-25 08:00AM	CrowdStrike Leads Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +9.36%
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
08:00AM	Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
Nov-07-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:27AM	Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised (Zacks)
11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks)
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks)
09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
08:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology (GlobeNewswire)
Oct-31-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-30-25 12:00PM	What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock (Zacks)
09:40AM	Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
08:00AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
Oct-29-25 09:08AM	Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues (Insider Monkey)
Oct-28-25 12:00PM	Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today (Motley Fool) +27.04%
11:37AM	Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. (Investor's Business Daily)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:30AM	Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire)
09:30AM	What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q3 2025 Earnings (GuruFocus.com)
Oct-24-25 08:00AM	Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-06-25 08:00AM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Oct-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.26%
Oct-01-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-29-25 04:00PM	Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire) +5.98%
11:38AM	Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025 (Investor's Business Daily)
09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
Sep-25-25 12:00PM	Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy (Zacks)
Sep-17-25 04:00AM	Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-16-25 09:00AM	Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award (GlobeNewswire)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Sep-11-25 11:17AM	Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream (Insider Monkey)
Sep-10-25 12:20AM	Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE (Insider Monkey)
Sep-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.80%
Sep-03-25 11:43AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Sep-01-25 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-19-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire) -5.79%
Aug-15-25 10:06AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily) +5.69%
Aug-14-25 09:55AM	Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know (Zacks)
Aug-11-25 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
Aug-08-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.07%
04:00PM	Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 09:49AM	Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +5.54%
Jul-30-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-23-25 04:00PM	Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (GlobeNewswire)
Jul-17-25 12:28PM	Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196% (Investor's Business Daily)
Jul-10-25 02:26PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily) +7.38%
Jul-09-25 12:55AM	Arcutis' ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis (Insider Monkey)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matsuda Masaru	See Remarks	Feb 02 '26	Sale	25.28	40,638	1,027,293	110,003	Feb 04 08:35 PM
Burnett Patrick	See Remarks	Feb 04 '26	Sale	25.81	9,794	252,748	80,651	Feb 04 07:30 PM
Burnett Patrick	See Remarks	Feb 02 '26	Sale	25.50	3,675	93,707	90,445	Feb 04 07:30 PM
Watanabe Todd	See Remarks	Feb 02 '26	Sale	25.50	19,833	505,710	721,306	Feb 04 07:25 PM
Vairavan Latha	SVP Chief Financial Officer	Feb 02 '26	Sale	25.50	1,320	33,658	63,607	Feb 04 07:24 PM
Welgus Howard G.	Director	Feb 02 '26	Sale	25.05	10,000	250,483	59,744	Feb 04 07:23 PM
Edwards Larry Todd	See Remarks	Feb 02 '26	Sale	25.50	2,052	52,323	148,865	Feb 04 07:21 PM
Patrick Burnett	Officer	Feb 04 '26	Proposed Sale	25.81	9,794	252,748		Feb 04 04:52 PM
Masaru Matsuda	officer	Feb 02 '26	Proposed Sale	25.28	40,638	1,027,275		Feb 02 06:19 PM
Todd Edwards	Officer	Feb 02 '26	Proposed Sale	25.50	2,052	52,323		Feb 02 06:17 PM
Latha Vairavan	Officer	Feb 02 '26	Proposed Sale	25.50	1,320	33,658		Feb 02 06:15 PM
Patrick Burnett	Officer	Feb 02 '26	Proposed Sale	25.50	3,675	93,707		Feb 02 05:48 PM
Todd Frank Watanabe	officer	Feb 02 '26	Proposed Sale	25.50	19,833	505,710		Feb 02 05:41 PM
Howard Welgus	Director	Feb 02 '26	Proposed Sale	25.05	10,000	250,483		Feb 02 05:04 PM
Burnett Patrick	See Remarks	Jan 05 '26	Sale	28.98	2,490	72,166	94,120	Jan 07 05:46 PM
Welgus Howard G.	Director	Jan 02 '26	Sale	28.96	10,000	289,606	69,744	Jan 06 05:31 PM
Patrick Burnett	Officer	Jan 05 '26	Proposed Sale	28.98	2,490	72,166		Jan 05 04:01 PM
Burnett Patrick	See Remarks	Dec 31 '25	Sale	29.20	1,697	49,560	96,610	Jan 02 06:12 PM
Howard Welgus	Director	Jan 02 '26	Proposed Sale	28.96	10,000	289,606		Jan 02 04:00 PM
Patrick Burnett	Officer	Dec 31 '25	Proposed Sale	29.21	1,697	49,561		Dec 31 04:01 PM
Burnett Patrick	See Remarks	Dec 15 '25	Option Exercise	3.64	11,500	41,860	109,807	Dec 17 05:53 PM
Burnett Patrick	See Remarks	Dec 15 '25	Sale	28.94	11,500	332,851	98,307	Dec 17 05:53 PM
Patrick Burnett	Officer	Dec 15 '25	Proposed Sale	28.94	11,500	332,851		Dec 15 04:07 PM
Matsuda Masaru	See Remarks	Dec 01 '25	Sale	30.23	1,657	50,091	150,641	Dec 03 05:24 PM
Welgus Howard G.	Director	Dec 01 '25	Sale	30.21	10,000	302,133	79,744	Dec 03 05:23 PM
Howard Welgus	Director	Dec 01 '25	Proposed Sale	30.21	10,000	302,133		Dec 01 04:07 PM
Masaru Matsuda	Officer	Dec 01 '25	Proposed Sale	30.23	1,657	50,091		Dec 01 04:06 PM
LIN SUE-JEAN	Director	Nov 24 '25	Option Exercise	8.31	25,272	210,011	52,007	Nov 25 06:27 PM
LIN SUE-JEAN	Director	Nov 24 '25	Sale	30.78	25,272	777,956	26,735	Nov 25 06:27 PM
Watanabe Todd	See Remarks	Nov 24 '25	Sale	30.36	48,945	1,485,755	740,537	Nov 24 06:45 PM
Watanabe Todd	See Remarks	Nov 21 '25	Sale	30.00	1,055	31,650	793,838	Nov 24 06:45 PM
Sue-Jean Lin	Director	Nov 24 '25	Proposed Sale	30.78	25,272	777,956		Nov 24 04:01 PM
Todd Franklin Watanabe	Officer	Nov 24 '25	Proposed Sale	30.36	48,945	1,485,755		Nov 24 03:55 PM
Matsuda Masaru	See Remarks	Nov 19 '25	Sale	28.29	2,550	72,135	151,476	Nov 21 06:34 PM
Gilbert Halley E	Director	Nov 20 '25	Option Exercise	7.51	12,220	91,772	38,655	Nov 21 06:21 PM
Gilbert Halley E	Director	Nov 20 '25	Sale	27.55	16,532	455,442	22,123	Nov 21 06:21 PM
Todd Franklin Watanabe	Officer	Nov 21 '25	Proposed Sale	30.00	1,055	31,650		Nov 21 04:49 PM
Halley Gilbert	Director	Nov 20 '25	Proposed Sale	27.55	16,532	455,442		Nov 20 04:24 PM
Masaru Matsuda	Officer	Nov 19 '25	Proposed Sale	28.29	2,550	72,133		Nov 19 04:20 PM
Krishnamohan Neha	Director	Nov 13 '25	Option Exercise	8.28	39,272	325,231	62,627	Nov 17 07:56 PM
Krishnamohan Neha	Director	Nov 13 '25	Sale	23.20	40,504	939,494	22,123	Nov 17 07:56 PM
Neha Krishnamohan	Director	Nov 13 '25	Proposed Sale	23.19	40,504	939,273		Nov 13 04:05 PM
Edwards Larry Todd	See Remarks	Nov 06 '25	Sale	25.16	29,131	732,927	150,193	Nov 10 05:42 PM
Burnett Patrick	See Remarks	Nov 06 '25	Option Exercise	3.64	17,250	62,790	115,575	Nov 10 05:41 PM
Burnett Patrick	See Remarks	Nov 06 '25	Sale	24.18	17,250	417,145	98,325	Nov 10 05:41 PM
Patrick Burnett	Officer	Nov 06 '25	Proposed Sale	24.18	17,250	417,145		Nov 06 05:49 PM
Burnett Patrick	See Remarks	Nov 05 '25	Sale	23.72	3,864	91,643	98,325	Nov 05 06:57 PM
Burnett Patrick	See Remarks	Nov 03 '25	Sale	24.72	2,622	64,806	102,189	Nov 05 06:57 PM
Welgus Howard G.	Director	Nov 03 '25	Sale	25.27	10,000	252,669	89,744	Nov 05 06:24 PM
Vairavan Latha	SVP Chief Financial Officer	Nov 03 '25	Sale	24.72	88	2,175	64,927	Nov 05 06:24 PM
Watanabe Todd	See Remarks	Nov 03 '25	Sale	24.72	11,547	285,399	794,893	Nov 05 06:23 PM
Matsuda Masaru	See Remarks	Nov 03 '25	Sale	24.72	7,208	178,156	154,026	Nov 05 06:23 PM
Patrick Burnett	Officer	Nov 05 '25	Proposed Sale	23.72	3,846	91,216		Nov 05 05:29 PM
Masaru Matsuda	Officer	Nov 03 '25	Proposed Sale	24.72	7,208	178,155		Nov 03 05:49 PM
Latha Vairavan	Officer	Nov 03 '25	Proposed Sale	24.72	88	2,175		Nov 03 05:48 PM
Todd Franklin Watanabe	Officer	Nov 03 '25	Proposed Sale	24.72	11,547	285,399		Nov 03 05:47 PM
Patrick Burnett	Officer	Nov 03 '25	Proposed Sale	24.72	2,622	64,806		Nov 03 05:47 PM
Howard Welgus	Director	Nov 03 '25	Proposed Sale	25.27	10,000	252,669		Nov 03 04:52 PM
Watanabe Todd	See Remarks	Oct 28 '25	Sale	25.03	40,000	1,001,032	806,440	Oct 30 07:02 PM
Todd F watanabe	officer	Oct 28 '25	Proposed Sale	25.03	40,000	1,001,033		Oct 28 04:06 PM
Edwards Larry Todd	See Remarks	Oct 02 '25	Sale	20.04	4,504	90,263	178,897	Oct 06 03:15 PM
Watanabe Todd	See Remarks	Oct 01 '25	Sale	19.33	24,261	469,074	867,179	Oct 03 05:02 PM
Watanabe Todd	See Remarks	Oct 02 '25	Sale	20.04	20,739	415,574	846,440	Oct 03 05:02 PM
Welgus Howard G.	Director	Oct 01 '25	Option Exercise	1.68	9,538	16,030	109,744	Oct 03 05:01 PM
Welgus Howard G.	Director	Oct 01 '25	Sale	18.92	10,000	189,227	99,744	Oct 03 05:01 PM
Todd Franklin Watanabe	Officer	Oct 02 '25	Proposed Sale	20.04	20,739	415,574		Oct 02 04:43 PM
Larry Todd Edwards	officer	Oct 02 '25	Proposed Sale	20.04	4,504	90,263		Oct 02 04:41 PM
Todd Franklin Watanabe	Officer	Oct 01 '25	Proposed Sale	19.33	24,261	469,074		Oct 01 05:35 PM
Howard Welgus	Director	Oct 01 '25	Proposed Sale	18.92	10,000	189,227		Oct 01 03:16 PM
Watanabe Todd	See Remarks	Sep 08 '25	Sale	17.54	9,625	168,799	891,944	Sep 10 06:21 PM
Watanabe Todd	See Remarks	Sep 09 '25	Sale	17.52	504	8,829	891,440	Sep 10 06:21 PM
Watanabe Todd	Officer	Sep 09 '25	Proposed Sale	17.52	504	8,829		Sep 09 03:17 PM
Matsuda Masaru	See Remarks	Sep 04 '25	Sale	16.16	36,130	583,716	161,234	Sep 08 05:14 PM
Watanabe Todd	Officer	Sep 08 '25	Proposed Sale	17.54	9,625	168,800		Sep 08 05:04 PM
Welgus Howard G.	Director	Sep 02 '25	Option Exercise	0.00	10,000	0	110,206	Sep 04 06:41 PM
Welgus Howard G.	Director	Sep 02 '25	Sale	15.64	10,000	156,383	100,206	Sep 04 06:41 PM
Matsuda Masaru	Officer	Sep 04 '25	Proposed Sale	16.16	36,130	583,716		Sep 04 04:21 PM
Welgus Howard G.	Director	Sep 02 '25	Proposed Sale	15.61	10,000	156,083		Sep 02 03:08 PM
Burnett Patrick	See Remarks	Aug 21 '25	Sale	15.57	2,438	37,969	104,811	Aug 21 09:32 PM
Burnett Patrick	See Remarks	Aug 19 '25	Sale	16.16	1,750	28,281	107,249	Aug 21 09:32 PM
Burnett Patrick	Officer	Aug 21 '25	Proposed Sale	15.57	2,438	37,969		Aug 21 05:27 PM
Burnett Patrick	Officer	Aug 19 '25	Proposed Sale	16.13	1,750	28,228		Aug 19 04:57 PM
Burnett Patrick	See Remarks	Aug 08 '25	Sale	14.03	3,847	53,988	108,999	Aug 12 05:04 PM
Topper David Joseph	Former Officer	Aug 08 '25	Proposed Sale	14.58	41,979	611,936		Aug 08 04:40 PM
Burnett Patrick	Officer	Aug 08 '25	Proposed Sale	14.03	3,847	53,989		Aug 08 04:10 PM
Topper David Joseph	Former Officer	Aug 06 '25	Proposed Sale	14.99	53,187	797,446		Aug 06 03:04 PM
Watanabe Todd	See Remarks	Aug 04 '25	Sale	14.33	11,547	165,429	901,569	Aug 05 06:29 PM
Burnett Patrick	See Remarks	Aug 04 '25	Sale	14.33	2,622	37,564	112,846	Aug 05 06:28 PM
Vairavan Latha	SVP Chief Financial Officer	Aug 04 '25	Sale	14.33	89	1,275	65,015	Aug 05 06:28 PM
Matsuda Masaru	See Remarks	Aug 04 '25	Sale	14.33	6,330	90,687	197,364	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Option Exercise	0.00	10,000	0	106,316	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Sale	14.30	10,000	142,982	100,206	Aug 05 06:28 PM
Watanabe Todd	Officer	Aug 04 '25	Proposed Sale	14.33	11,547	165,429		Aug 04 03:43 PM
Burnett Patrick	Officer	Aug 04 '25	Proposed Sale	14.33	2,622	37,564		Aug 04 03:42 PM
Matsuda Masaru	Officer	Aug 04 '25	Proposed Sale	14.33	6,330	90,687		Aug 04 03:40 PM
Vairavan Latha	Officer	Aug 04 '25	Proposed Sale	14.10	89	1,255		Aug 04 03:38 PM
Welgus Howard G.	Director	Aug 01 '25	Proposed Sale	14.30	10,000	142,982		Aug 01 04:20 PM
Burnett Patrick	See Remarks	Jul 10 '25	Option Exercise	0.00	23,000	0	138,468	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 14 '25	Option Exercise	0.00	5,750	0	121,218	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 10 '25	Sale	15.05	23,000	346,046	115,468	Jul 14 04:02 PM

MIRM

Mirum Pharmaceuticals Inc

MBX

MBX Biosciences Inc

ARQT

Arcutis Biotherapeutics Inc

Upgrade your FINVIZ experience